(VIANEWS) – WENDEL (MF.PA), ASR NEDERLAND (ASRNL.AS), TF1 (TFI.PA) are the highest payout ratio stocks on this list.
We have congregated information concerning stocks with the highest payout ratio so far. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. WENDEL (MF.PA)
198.68% Payout Ratio
Wendel is a private equity firm specializing in equity financing in middle markets and later stages through leveraged buy-out and transactions and acquisitions. It invests in both listed and non-listed companies. The firm typically invests in technology services and software, business services, healthcare and industrial technology. The firm seeks to invest in Africa, Europe, European Developed Markets, Western Europe, particularly France, and North America (United States and Canada). It invests between €150 million ($175.46 million) and €500 million ($584.87 million) in companies. It targets majority/control/large minority investments in listed or unlisted companies. The firm seeks to take a seat on the board of directors or supervisory board and key committees of its portfolio companies. It makes balance sheet investments. Wendel was founded in 1704 and is headquartered in Paris, France with additional offices across Asia, North America, United Kingdom and Europe.
Earnings Per Share
As for profitability, WENDEL has a trailing twelve months EPS of €1.51.
PE Ratio
WENDEL has a trailing twelve months price to earnings ratio of 61.95. Meaning, the purchaser of the share is investing €61.95 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.6%, now sitting on 8.7B for the twelve trailing months.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 19, 2023, the estimated forward annual dividend rate is 3.2 and the estimated forward annual dividend yield is 3.44%.
More news about WENDEL.
2. ASR NEDERLAND (ASRNL.AS)
58.37% Payout Ratio
ASR Nederland N.V. provides insurance, pensions, and mortgages products for consumers, self-employed persons, and companies. It operates through five segments: Non-Life, Life, Asset Management, Distribution and Services, and Holding and Other. The company offers health, life, pension, funeral expense, and occupational disability insurance products; and non-life insurance products, including road traffic, fire, third-party liability and legal assistance insurance. It also provides financial intermediary services; and develops real estate properties, as well as operates as an asset manager for third parties. ASR Nederland N.V. offers its products under the Loyalis, Ditzo, Europeesche Verzekeringen, a.s.r. asset management, Ardanta, and a.s.r. brand names. The company was formerly known as Fortis Verzekeringen Nederland N.V. and changed its name to ASR Nederland N.V. in October 2008. ASR Nederland N.V. was founded in 1720 and is headquartered in Utrecht, the Netherlands.
Earnings Per Share
As for profitability, ASR NEDERLAND has a trailing twelve months EPS of €4.4.
PE Ratio
ASR NEDERLAND has a trailing twelve months price to earnings ratio of 9.25. Meaning, the purchaser of the share is investing €9.25 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.26%.
Volume
Today’s last reported volume for ASR NEDERLAND is 48295 which is 89.32% below its average volume of 452229.
Moving Average
ASR NEDERLAND’s worth is higher than its 50-day moving average of €39.51 and under its 200-day moving average of €41.39.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 2, 2023, the estimated forward annual dividend rate is 2.7 and the estimated forward annual dividend yield is 6.78%.
More news about ASR NEDERLAND.
3. TF1 (TFI.PA)
56.25% Payout Ratio
TF1 SA engages in the broadcasting, studios and entertainment, and digital businesses in France and internationally. The company offers DTT channels, including TMC, TFX, and TF1 Séries Films; Theme channels, such as TV Breizh, Ushuaïa TV, and Histoire TV; e-TF1; websites; and advertising services, as well as TF1, which covers sports, French drama, news, entertainment, sports, and movies. It also operates studios, including Newen Studios; TF1 Studio; and entertainment channel comprising TF1 Entertainment. In addition, the company operates Unify, a digital channel. Further, it offers digital content management, theme channel, content/broadcasting internet and TV, and TV news images agency services, as well as engages in the acquisition/sale of audiovisual rights and e-commerce activities. TF1 SA was incorporated in 1982 and is headquartered in Boulogne-Billancourt, France.
Earnings Per Share
As for profitability, TF1 has a trailing twelve months EPS of €0.8.
PE Ratio
TF1 has a trailing twelve months price to earnings ratio of 7.91. Meaning, the purchaser of the share is investing €7.91 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.57%.
Moving Average
TF1’s value is way below its 50-day moving average of €7.10 and way below its 200-day moving average of €7.06.
Yearly Top and Bottom Value
TF1’s stock is valued at €6.32 at 12:10 EST, way under its 52-week high of €8.71 and way above its 52-week low of €5.56.
More news about TF1.
4. MERCK AND CO INC (MRK.PA)
55.47% Payout Ratio
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Earnings Per Share
As for profitability, MERCK AND CO INC has a trailing twelve months EPS of €4.82.
PE Ratio
MERCK AND CO INC has a trailing twelve months price to earnings ratio of 21.04. Meaning, the purchaser of the share is investing €21.04 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.69%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 14, 2023, the estimated forward annual dividend rate is 2.7 and the estimated forward annual dividend yield is 2.61%.
Moving Average
MERCK AND CO INC’s worth is below its 50-day moving average of €103.30 and higher than its 200-day moving average of €99.53.
Volume
Today’s last reported volume for MERCK AND CO INC is 250 which is 69.43% below its average volume of 818.
More news about MERCK AND CO INC.
5. TUBIZE-FIN (TUB.BR)
39.2% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.92.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 36.41. Meaning, the purchaser of the share is investing €36.41 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €69.90 at 12:10 EST, way below its 52-week high of €80.20 and higher than its 52-week low of €65.40.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 1.18%.
Volume
Today’s last reported volume for TUBIZE-FIN is 962 which is 85.31% below its average volume of 6550.
More news about TUBIZE-FIN.
